DotBio develops multi-functional antibodies based on its proprietary DotBody technology as the next generation of cancer therapies.
DotBio has raised $5.6M in total funding. The most recent round was Seed. The last funding was announced in August 2023.
DotBio's investors include Gaorong Capital, Enterprise Singapore, Prox Ventures, AIM-HI Accelerator Fund.
DotBio is headquartered in Singapore, Singapore.
DotBio develops multi-functional antibodies based on its proprietary DotBody technology as the next generation of cancer therapies.
DotBio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"DotBio — Funding & Investors." VCBacked, August 7, 2023, https://www.vcbacked.co/company/dotbio. Accessed July 20, 2026.
VCBacked. (2023). DotBio — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/dotbio
{{cite web |title=DotBio — Funding & Investors |url=https://www.vcbacked.co/company/dotbio |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated